Pricing Log in Create free account

RenovoRx, Inc. (RNXT) vs Xilio Therapeutics, Inc. (XLO)

RenovoRx, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. RenovoRx, Inc. and Xilio Therapeutics, Inc. are of similar size ($55.9M and $53.7M). Xilio Therapeutics, Inc. has the higher net margin (−34.1% vs −469.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Xilio Therapeutics, Inc. leads on 11 and RenovoRx, Inc. on 3.

Valuation

Metric RNXT XLO Biotechnology median
P/E n/m n/m 10.60
P/S 19.79 2.61 9.40
P/B 5.92 2.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 17.77 0.51 9.02
Earnings yield (27.19%) (17.27%) (32.88%)
Free cash flow yield (22.25%) (36.59%) (23.13%)

Profitability

Metric RNXT XLO Biotechnology median
Gross margin 84.04% 100.00% 68.51%
Operating margin (489.05%) (48.94%) 0.00%
Net margin (469.02%) (34.06%) 0.00%
Free cash flow margin (440.38%) (95.59%) 0.00%
Return on equity (149.98%) (55.03%) (51.96%)
Return on assets (110.14%) (15.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RNXT XLO Biotechnology median
Revenue growth (TTM) — 327.25% 6.76%
EPS growth (last fiscal year) 20.00% 72.55% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RNXT XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.65 4.25 4.97
Net debt to EBITDA 0.56 3.40 1.01

Dividend

Metric RNXT XLO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RNXT XLO Biotechnology median
Market cap 53.70m 55.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack